

WORKING GROUP INFORMATIONS

1. Members of the Working Group

Please complete / modify these information if appropriate

Christoph Gradmann	Institute of General Practice and Community Medicine University of Oslo Frederik Holst hus P.O. Box 1130 Blindern Oslo 0318 - Norway Phone: 0047 228 50615 Fax: 0047 228 50590
Siri Jensen	Institute of General Practice and Community Medicine University of Oslo Frederik Holst hus P.O. Box 1130 Blindern Oslo 0318 - Norway Phone 0047 22850655 Fax: 0047 228 50590
Larsen Oivind	Institute of General Practice and Community Medicine University of Oslo Frederik Holst hus P.O. Box 1130 Blindern Oslo 0318 - Norway Phone 0047 22850673 Fax: 0047 228 50590
Anne Kveim Lie	Institute of General Practice and Community Medicine of Oslo University P.O. Box 1130 Blindern Oslo 0318 – Norway Phone 0047 2285607 Fax: 0047 228 50590

2. Please, enter the name of the person you have appointed as local head of the working group:

Christoph Gradmann

3. Working Plan

Please, complete/modify or add if appropriate:

Autumn 2010

Thematic Workshop I: Standardizing Clinical Research and Bedside Evaluation: Antibiotics Resistance and Nosocomial Infections. Organisation: Gradmann, Lie / Place: Oslo, N

Topic: The application of antibiotics after World War II was followed by the development of numerous resistances to such medicines in many common pathogenic microbes. While this was initially seen as a problem that could be tackled by switching to other preparations or modifying the protocols for application, three fundamental issues developed over time that the workshop will chiefly focus on: First, it was precisely the features of antibiotics as mass-produced and standardised medicine that facilitated the development of resistant strains. Secondly, hospitals that had been designed as hygienic places, became the sites of novel epidemiologies that facilitated the production and dissemination of new or modified pathogens. Thirdly, over the decades matters of health and disease became ever more closely associated with the technology that had been designed to prevent or cure diseases in the first place. What was an important issue in the mid-1950s in relation to 'classical' pathogenic germs such as *Staphylococcus aureus*, later on and in relation to patients with modified immunity expanded into the production of a host of emerging infections caused by 'non-classical' microbes.

Co-Financing by: University of Oslo

Referents (inter alia): N Paul, I Buelzingsloewen, R Bud, F Condrau, JP Gaudilliere

The working group has started a project on the history of antibiotic resistance in Norway. CG is project leader, Anne Kveim Lie is employed on a postdoctoral position funded by the Norwegian Research Council. Siri Jensen is working on a doctoral thesis which is based on an interview study on practices regarding the handling of antibiotic resistance in medicine and health care. Her position and funding are with the Antibiotics Center for Primary Health Care of Oslo University (ASP), with whom the working group collaborates closely.

4. Last publications in the field

Please complete / modify these information if appropriate

(citation in Harvard-Style would be great. Example: V. E. Kinsey et al., 'Cooperative study of retrolental fibroplasia and the use of oxygen', *Archives of Ophthalmology*, 56 (1956), 481–543.)

5. New fundings (third party) in relation to DRUGS

Please complete / modify these information if appropriate

A postdoc grant worth 3 years of full employment was awarded by the Norwegian Research Council. Projectleader is Christoph Gradmann, Anne Kveim Lie is employed in the postdoc position. Topic under research is the history of antibiotic resistance in Norway. The project cooperates with with the antibiotics group of the ESF Drugs Network

6. Special ressources and facilities

Please complete / modify these information if appropriate